Howard B. Rosen

Kala Pharmaceuticals, Inc., a leading developer of innovative products that enhance penetration of therapeutic agents into ocular tissue based on the Company’s proprietary Mucus Penetrating Particle (MPP) technology, today announced the appointment of Howard B. Rosen as Chairman of the company’s board of directors.

“Howard’s extensive track record of building and guiding successful companies will be extremely helpful to Kala at this critical juncture as we advance a rich pipeline of ophthalmology product candidates into clinical development,” said Guillaume Pfefer, Ph.D., Kala’s President and Chief Executive Officer. “Howard is an experienced visionary and is ideally suited to provide leadership guidance for Kala to evolve to the next level with broad applications for our MPP technology, not only in ocular diseases but also other potential indications involving mucus tissues including respiratory and gastrointestinal disease.”

Commenting on his appointment to the Kala board, Mr. Rosen said, “Upon first introduction to Kala, I was immediately impressed by the many attributes of Kala’s MPP technology which open up a breadth of opportunities across a wide range of diseases. I look forward to leveraging my experience to guide Kala as it continues to grow and evolve.”